Guggenheim raised its price target on Bristol-Myers Squibb Company (BMY) to $72 and reiterated a Buy rating on February 6, 2026. Bank of America also raised its price target to $68 from $64 while maintaining a Buy rating. Wells Fargo analyst Mohit Bansal raised his price target to $60 from $55 with an Equal Weight rating. Citi lifted its price target to $64 from $60 while reiterating a Neutral rating. Bristol Myers reported fourth-quarter revenue of $12.5 billion, exceeding estimates. The company anticipates a data-rich 2026 with pivotal pipeline readouts expected in the second half of the year.

Read more at Yahoo Finance: Guggenheim Raises its Price Target on Bristol-Myers Squibb Company (BMY) to $72 and Reiterates a Buy Rating